Search research articles
Contact Us
Filters
Showing results (181-190 of 221) with videos related to
Page
of 23
Sort By:
The Journal of Urology
|
November 9, 2022
Reply by Authors
Brian De, Dario Pasalic, Daniel A Barocas, et al.
European Urology
|
April 28, 2026
Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials
Alexander D Sherry, Van To, Criselle D'souza, et al.
The Journal of Urology
|
August 25, 2022
Patient-reported Outcomes After External Beam Radiotherapy With Low Dose Rate Brachytherapy Boost vs Radical Prostatectomy for Localized Prostate Cancer: Five-year Results From a Prospective Comparative Effectiveness Study
Brian De, Dario Pasalic, Daniel A Barocas, et al.
Cancer Research
|
November 9, 2016
Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy
Xiaohong Wang, Jonathan E Schoenhals, Ailin Li, et al.
British Journal of Cancer
|
April 27, 2018
Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers
Shiraj Sen, Shumei Kato, Rishi Agarwal, et al.
Cancer Research Communications
|
August 5, 2024
Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials
Esther J Beck, Alexander D Sherry, Marcus A Florez, et al.
Journal for Immunotherapy of Cancer
|
September 6, 2019
Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy
Hari Menon, Dawei Chen, Rishab Ramapriyan, et al.
BMJ Supportive & Palliative Care
|
June 6, 2024
Single-fraction radiation retreatment for bone metastases: role of a rapid access clinic
Minsoo Kim, Jose Alberto Maldonado, Prasamsa Pandey, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
February 7, 2012
Three differentiation states risk-stratify bladder cancer into distinct subtypes
Jens-Peter Volkmer, Debashis Sahoo, Robert K Chin, et al.
The Lancet. Oncology
|
March 6, 2025
ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial
Giulia Marvaso, Giulia Corrao, Mattia Zaffaroni, et al.
Page
of 23
Search research articles
Search
Showing results (181-190 of 221) with videos related to
Sort By:
Page
of 23
The Journal of Urology
|
November 9, 2022
Reply by Authors
Brian De, Dario Pasalic, Daniel A Barocas, et al.
European Urology
|
April 28, 2026
Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials
Alexander D Sherry, Van To, Criselle D'souza, et al.
The Journal of Urology
|
August 25, 2022
Patient-reported Outcomes After External Beam Radiotherapy With Low Dose Rate Brachytherapy Boost vs Radical Prostatectomy for Localized Prostate Cancer: Five-year Results From a Prospective Comparative Effectiveness Study
Brian De, Dario Pasalic, Daniel A Barocas, et al.
Cancer Research
|
November 9, 2016
Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy
Xiaohong Wang, Jonathan E Schoenhals, Ailin Li, et al.
British Journal of Cancer
|
April 27, 2018
Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers
Shiraj Sen, Shumei Kato, Rishi Agarwal, et al.
Cancer Research Communications
|
August 5, 2024
Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials
Esther J Beck, Alexander D Sherry, Marcus A Florez, et al.
Journal for Immunotherapy of Cancer
|
September 6, 2019
Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy
Hari Menon, Dawei Chen, Rishab Ramapriyan, et al.
BMJ Supportive & Palliative Care
|
June 6, 2024
Single-fraction radiation retreatment for bone metastases: role of a rapid access clinic
Minsoo Kim, Jose Alberto Maldonado, Prasamsa Pandey, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
February 7, 2012
Three differentiation states risk-stratify bladder cancer into distinct subtypes
Jens-Peter Volkmer, Debashis Sahoo, Robert K Chin, et al.
The Lancet. Oncology
|
March 6, 2025
ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial
Giulia Marvaso, Giulia Corrao, Mattia Zaffaroni, et al.
Page
of 23